Related Experiment Videos
[Thoracic adenoid cystic carcinomas].
C Le Péchoux1, P Baldeyrou, I Ferreira
1Service de radiothérapie, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94000Villejuif, France. lepechoux@igr.fr
Summary
Adenoid cystic carcinomas, a rare tracheal tumor, are often diagnosed late due to slow growth. Treatment involves surgery and radiotherapy, with survival rates varying by stage and treatment approach.
Area of Science:
- Oncology
- Pulmonology
- Pathology
Context:
- Adenoid cystic carcinomas (ACCs) are rare but constitute approximately 40% of all tracheal tumors.
- These tumors exhibit slow growth, frequently leading to diagnosis at advanced stages.
- Intrathoracic localizations include the carena and proximal airways.
Purpose:
- To review the characteristics, diagnosis, and treatment of adenoid cystic carcinomas in the trachea.
- To discuss the role of surgery and radiotherapy in managing limited and inoperable tracheal tumors.
- To highlight survival rates and future therapeutic considerations for advanced or recurrent disease.
Summary:
- Pathological identification of tracheal ACCs can be challenging.
- Treatment for localized tumors typically involves surgical resection, often combined with radiotherapy, with doses ranging from 45 to 65 Gy based on margin status.
- For inoperable cases, exclusive radiotherapy exceeding 60 Gy is recommended, though survival rates are lower (12-27%) in heterogeneous patient groups.
Impact:
- Surgery combined with postoperative radiotherapy yields 5-year survival rates of 65-80% for localized tracheal ACCs.
- Effective radiotherapy doses are crucial for improving outcomes in both operable and inoperable tracheal tumors.
- Future research into targeted therapies is warranted due to the chemo-resistant nature and late recurrence patterns of ACCs.